What Is TB500 Same as TB-500? (Nomenclature Explained)

What Is TB500 Same as TB-500? (Nomenclature Explained)

Research peptide nomenclature remains one of the most confusing aspects of biological sourcing. Not because the chemistry is complex, but because naming conventions vary by manufacturer, publication, and even lab protocol documentation. TB500 and TB-500 represent the same synthetic peptide derived from Thymosin Beta-4, yet the hyphen variation creates unnecessary confusion for researchers who assume the punctuation signals a structural or functional difference. It doesn't. The molecule is identical whether you write it as TB500, TB-500, TB 500, or even Tβ4 Fragment 17-23 in certain academic contexts.

We've worked with research institutions across immunology, tissue regeneration, and wound healing studies for years. The single most common sourcing error we see is researchers ordering from multiple suppliers under the assumption that TB500 from one vendor and TB-500 from another represent different compounds. They're buying duplicate inventory without realizing it.

What is TB500 same as TB-500?

Yes, TB500 is the same peptide as TB-500. Both designations refer to a synthetic analog of Thymosin Beta-4, a naturally occurring 43-amino-acid protein that regulates actin polymerization and cellular migration. The hyphen reflects stylistic preference or vendor branding. The amino acid sequence, molecular weight (approximately 4.9 kDa), and biological activity remain identical. Researchers use both terms interchangeably in published literature and procurement documentation.

The confusion stems from inconsistent naming standards across peptide synthesis facilities. Unlike pharmaceuticals with standardized International Nonproprietary Names (INNs), research-grade peptides are identified by lab shorthand, and TB500 falls into that category. Some manufacturers adopted the hyphenated version (TB-500) early in commercial production to distinguish it from unrelated compounds with similar acronyms. Others dropped the hyphen for simplicity. Neither choice alters the peptide's molecular structure, mechanism of action, or experimental utility. What matters is the amino acid sequence verification provided in the certificate of analysis (COA). If the sequence matches positions 1-43 of native Thymosin Beta-4, you have the correct compound regardless of how the label punctuates it.

TB500 and TB-500: Identical Amino Acid Sequence, Different Marketing

The core identity of any peptide lies in its amino acid sequence, not its name. TB500 and TB-500 both consist of the same 43-amino-acid chain derived from the N-terminal region of Thymosin Beta-4. The full sequence reads: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser. Molecular weight is approximately 4963.44 g/mol. If you receive a peptide labeled TB500 from one supplier and TB-500 from another, run both through mass spectrometry. You'll see identical peaks at 4963 m/z confirming they're the same molecule.

Manufacturers choose hyphenated or non-hyphenated formatting based on internal branding strategy. Some labs argue the hyphen improves readability when the designation appears in dense technical documentation. Others prefer the streamlined look of TB500 in product catalogs and publications. The European Peptide Society and the American Peptide Society have never issued formal guidance on this distinction because it's not a chemical issue. It's typographic. What researchers must verify is purity (typically ≥98% by HPLC for research applications), endotoxin levels (<1 EU/mg for in vivo studies), and sequence confirmation via mass spectrometry or amino acid analysis. These parameters define peptide quality; the hyphen does not.

In our experience sourcing peptides for tissue engineering and regenerative research, the naming variation causes procurement delays when institutions implement rigid inventory systems that treat TB500 and TB-500 as separate stock-keeping units (SKUs). Labs order both, expecting functional differences, only to discover through COA review that they've purchased duplicate material. We've seen research budgets waste thousands on redundant orders because catalog systems didn't flag the equivalence. The solution: establish a master synonym list in your lab's database linking all known variants (TB500, TB-500, Thymosin Beta-4 fragment) to a single internal identifier. This prevents duplicate purchasing and streamlines reorder workflows. High-purity research peptides demand precision in handling, storage, and application. TB 500 Thymosin Beta 4 from Real Peptides includes full amino acid sequencing verification and third-party purity testing in every batch, ensuring researchers receive exactly what the label promises regardless of punctuation preference.

Why Thymosin Beta-4 Became TB500 (and TB-500) in Research Contexts

Thymosin Beta-4 was first isolated from calf thymus tissue in the 1960s by biochemist Allan Goldstein at Albert Einstein College of Medicine. The protein plays a central role in wound healing, angiogenesis, and cellular migration by sequestering actin monomers and preventing premature polymerization. Its regenerative properties attracted attention from trauma research, cardiovascular repair studies, and tissue engineering labs worldwide. However, native Thymosin Beta-4 is a 43-amino-acid peptide with limited commercial availability and high production costs when extracted from biological tissue. Synthetic production solved the supply problem. And that's when the naming fragmented.

The designation TB500 emerged in the early 2000s when peptide synthesis companies began offering a synthetic version of the full-length Thymosin Beta-4 sequence for research purposes. The "TB" abbreviation stands for Thymosin Beta, and "500" originally referenced an internal product code at one of the first commercial suppliers. Other manufacturers adopted the name because it had already gained traction in published studies, but some added the hyphen to distinguish their product branding. No regulatory body standardized the nomenclature because TB500 is not an FDA-approved pharmaceutical. It exists in the research domain, where naming conventions follow lab tradition rather than pharmacopeial rules.

Academic publications compound the confusion by using multiple names interchangeably within the same paper. A single study might refer to the peptide as Thymosin Beta-4 in the abstract, TB-500 in the methods section, and Tβ4 in figure legends. All three refer to the same molecule. Researchers reading across multiple journals must parse these variations without assuming chemical differences. The bioavailability, half-life (approximately 2.5 hours in circulation), and receptor-binding affinity remain constant whether the label reads TB500 or TB-500. What changes is the vendor, synthesis method (solid-phase peptide synthesis is standard), and post-synthesis purification protocol. Factors that affect purity and endotoxin contamination but have nothing to do with the name.

From a practical standpoint, the TB500 designation simplified communication among researchers who needed shorthand for procurement and protocol documentation. Typing "Thymosin Beta-4 synthetic analog" repeatedly in a 20-page grant application wastes space; TB500 conveys the same information in five characters. The hyphenated variant (TB-500) likely arose when early adopters mistakenly added punctuation assuming it mirrored naming conventions from other peptide families like BPC-157 or Ipamorelin, where hyphens separate structural descriptors. Once both versions appeared in published literature, the bifurcation became permanent. Researchers cite papers using TB-500, suppliers catalog it as TB500, and institutional review boards see both on the same protocol submission. The absence of a unified standard reflects the decentralized nature of peptide research. Unlike pharmaceutical compounds governed by WHO naming conventions, research peptides operate in a naming Wild West where function matters more than formatting.

TB500 Same as TB-500: Comparison Across Key Research Parameters

Researchers often wonder whether the naming variation signals differences in formulation, purity standards, or intended applications. The table below compares TB500 and TB-500 across parameters critical to experimental design and procurement decisions.

Key Takeaways

• TB500 and TB-500 are identical synthetic peptides consisting of the same 43-amino-acid sequence derived from Thymosin Beta-4, with a molecular weight of approximately 4963 g/mol.
• The hyphen represents a stylistic or branding choice by peptide manufacturers and has no impact on amino acid sequence, molecular weight, or biological activity.
• Naming inconsistency across suppliers and academic publications causes procurement errors when researchers assume the punctuation indicates different compounds or formulations.
• Purity verification via HPLC, mass spectrometry, and certificate of analysis (COA) review is mandatory regardless of whether the label reads TB500 or TB-500.
• Both designations appear interchangeably in peer-reviewed literature, with no regulatory body establishing a standardized nomenclature for research-grade peptides.
• Storage and reconstitution protocols remain identical: lyophilized powder stored at -20°C, reconstituted solutions refrigerated at 2-8°C and used within 28 days.

What If: TB500 Nomenclature Scenarios

What If My Lab Ordered Both TB500 and TB-500 From Different Vendors?

You've purchased duplicate inventory. Verify by comparing the amino acid sequences listed in each vendor's certificate of analysis (COA). If both match the 43-residue Thymosin Beta-4 sequence and show molecular weights near 4963 g/mol, they're the same peptide. Consolidate your stock, update your inventory system to treat TB500 and TB-500 as synonyms, and use the redundant supply for validation experiments comparing batch-to-batch variability. This situation is common in multi-lab institutions where different researchers order from preferred suppliers without cross-checking nomenclature.

What If a Published Protocol Specifies TB-500 But My Supplier Only Stocks TB500?

Proceed with your supplier's TB500. The protocol author used the hyphenated format based on their vendor's labeling, not because the hyphen confers functional importance. Cross-reference the molecular weight and sequence in the protocol's supplementary materials with your supplier's COA. If they match, you have the correct compound. Academic authors rarely specify peptide formatting intentionally; they replicate the exact label from the vial they used. The key verification is sequence identity, not typographic convention.

What If I'm Submitting a Grant or IACUC Protocol — Should I Use TB500 or TB-500?

Choose one format and apply it consistently throughout your documentation. Most institutional review boards and funding agencies don't enforce peptide naming standards because no universal convention exists. However, include the full chemical name (Thymosin Beta-4 synthetic analog) in parentheses after the first mention to eliminate ambiguity for reviewers unfamiliar with the shorthand. Example: "Experiments will use TB-500 (Thymosin Beta-4 synthetic analog, 43 amino acids, CAS 77591-33-4) at concentrations ranging from 1-10 µM." This approach satisfies both technical precision and readability requirements.

What If the COA Shows a Molecular Weight of 4950 g/mol Instead of 4963 g/mol?

A deviation of ~13 g/mol is within acceptable variance for lyophilized peptides measured by mass spectrometry, which accounts for ion adducts, salt forms, and hydration state. However, if the discrepancy exceeds 20 g/mol or if the HPLC purity falls below 95%, contact your supplier for batch clarification. Some manufacturers produce acetate or trifluoroacetate salt forms that slightly alter the measured mass without affecting biological activity. The COA should specify the exact salt form used during synthesis. Request this information if it's absent, as it affects reconstitution calculations and molarity conversions in experimental protocols.

The Blunt Truth About TB500 vs TB-500 Naming

Here's the honest answer: the hyphen means nothing. It's a vendor branding artifact that became entrenched in research nomenclature before anyone thought to standardize it. The same peptide is sold under both labels because manufacturers know researchers will order whichever format they saw cited in the last paper they read. No chemical difference exists. No functional difference exists. No regulatory body cares which you use. The only thing that matters is verifying the amino acid sequence in the COA matches the 43-residue Thymosin Beta-4 structure you need for your experiment. If it does, you have the right peptide. Whether the label says TB500, TB-500, or "magic repair molecule" is irrelevant to your assay's outcome. Stop overthinking the punctuation and start scrutinizing the purity data, endotoxin levels, and storage conditions that actually affect experimental reproducibility. The peptide research field tolerates this naming chaos because function trumps formatting. And that's unlikely to change until a regulatory framework forces standardization, which won't happen for non-pharmaceutical research compounds.

Peptide quality depends on synthesis precision, not naming conventions. Every batch leaving a reputable facility undergoes HPLC verification, mass spectrometry, and amino acid analysis to confirm the sequence matches the intended target. The designation on the label is the last thing that determines whether your wound healing assay, angiogenesis study, or tissue regeneration protocol succeeds. What determines success is whether the peptide was synthesized correctly, purified to ≥98%, stored at appropriate temperatures, and reconstituted following sterile protocols. A lab that fixates on whether to order TB500 or TB-500 but ignores the COA's purity percentage, endotoxin count, and batch-to-batch variability is optimizing the wrong variable. We've seen researchers delay experiments by weeks debating nomenclature while using peptides stored improperly or reconstituted with non-sterile water. That's where experimental failure occurs, not in the presence or absence of a hyphen.

If you're sourcing peptides for rigorous biological research, establish vendor qualification criteria that prioritize analytical documentation over naming consistency. Require third-party purity verification, endotoxin testing below 1 EU/mg for in vivo work, and sequence confirmation via both mass spectrometry and amino acid analysis. Accept TB500, TB-500, and Thymosin Beta-4 as interchangeable designations in your inventory system, but reject any supplier who can't provide a COA with these parameters clearly documented. That's the standard we maintain across our full peptide collection. Small-batch synthesis with exact amino-acid sequencing verification for every vial, guaranteeing that what you order is what you receive regardless of how the name is formatted on the procurement form.

The research peptide industry would benefit from unified nomenclature, but until that happens, responsibility falls on individual researchers to verify molecular identity through analytical data rather than assuming label formatting signals compound differences. TB500 is TB-500. The hyphen is typographic noise. Focus on the chemistry.

Comparing TB500 to Related Regenerative Peptides

Researchers exploring tissue repair and cellular migration often evaluate TB500 alongside other peptides with overlapping but distinct mechanisms. Understanding these functional differences prevents protocol design errors and clarifies when TB500 (or TB-500) is the optimal choice versus alternatives like BPC-157, GHK-CU, or Thymosin Alpha-1. TB500 operates primarily through actin sequestration, binding to G-actin monomers via its conserved actin-binding domain to prevent premature filament formation. This mechanism promotes cellular migration by maintaining a pool of unpolymerized actin available for lamellipodia extension and stress fiber remodeling. Critical processes in wound closure, angiogenesis, and endothelial cell sprouting.

BPC-157, a 15-amino-acid gastric peptide derivative, influences vascular endothelial growth factor (VEGF) expression and nitric oxide pathways but lacks the direct actin-binding activity that defines TB500's mechanism. Studies comparing the two in tendon repair models show TB500 accelerates early-stage cellular infiltration into damaged tissue, while BPC-157 demonstrates stronger effects on collagen deposition and inflammatory modulation. They're not interchangeable. TB500 excels in migration-dependent processes, BPC-157 in stabilization and repair phase enhancement. Researchers studying acute injury response may combine both in sequential protocols: TB500 during the inflammatory and proliferative phases to promote cell recruitment, followed by BPC-157 during the remodeling phase to optimize matrix organization.

GHK-CU (Gly-His-Lys complexed with copper) operates through entirely different pathways, binding to cellular receptors that upregulate metalloproteinase activity and extracellular matrix remodeling genes. Its copper-binding capacity allows it to modulate oxidative stress and stimulate angiogenesis through mechanisms unrelated to actin dynamics. TB500 and GHK-CU are often confused because both promote wound healing, but their molecular targets share no overlap. Thymosin Alpha-1, despite the similar name, is an immunomodulatory peptide derived from a different region of the prothymosin alpha precursor protein. It enhances T-cell differentiation and cytokine production rather than affecting cytoskeletal dynamics. Researchers must select based on the specific cellular process under investigation: actin remodeling and migration (TB500), immune modulation (Thymosin Alpha-1), or matrix metalloproteinase regulation (GHK-CU). Misapplication wastes research budgets and produces inconclusive data.

We work with labs designing multi-peptide protocols across regenerative medicine, cardiovascular repair, and dermatological research. The most effective experimental designs pair peptides with non-overlapping mechanisms rather than stacking compounds that target the same pathway. Combining TB500 with Thymalin or Epithalon in longevity studies addresses both cellular migration capacity and telomere maintenance. Orthogonal mechanisms that produce additive rather than redundant effects. The key is understanding that TB500's primary value lies in its actin-sequestering activity, which no other commonly used research peptide replicates. If your experimental model depends on enhanced cellular motility, directional migration, or angiogenic sprouting, TB500 (or TB-500, same peptide) is the mechanistically appropriate choice. If your model prioritizes collagen synthesis, immune response, or antioxidant capacity, other peptides deliver more targeted effects.

Peptide research demands precision in both compound selection and experimental design. The nomenclature variation between TB500 and TB-500 is irrelevant compared to the functional differences between TB500 and structurally unrelated peptides marketed for similar applications. Verify the mechanism, confirm the sequence, validate the purity. Those factors determine experimental outcomes. The hyphen never will.